Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study

SIMPLE SUMMARY: Carfilzomib with dexamethasone is an important therapeutic option for patients with relapsed/refractory multiple myeloma. We sought to evaluate the effect of this regimen on the bone-related outcomes, which are associated with both quality of life and survival. Among 25 patients, les...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancers (Basel)
Главные авторы: Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Katodritou, Eirini, Kyrtsonis, Marie-Christine, Douka, Vassiliki, Spanoudakis, Emmanouil, Papatheodorou, Athanasios, Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Gavriatopoulou, Maria, Makras, Polyzois, Kastritis, Efstathios, Dimopoulos, Meletios A
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2021
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7998249/
https://ncbi.nlm.nih.gov/pubmed/33809268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13061257
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы